Health Technology

Dr. Reddy's Laboratories Ltd.

In the news

Bangladesh's Beximco thrives on coronavirus challenges Jul 26, 2020
Fujifilm partners with India's Dr. Reddy's to sell Avigan overseas Jul 1, 2020
Investors trawl for bargains in depressed Asian markets Apr 3, 2020
Cipla profit rises on strong growth in India, US businesses Feb 5, 2020
Dr. Reddy's posts surprise quarterly loss on impairment charges Jan 27, 2020

See more articles on Dr. Reddy's Laboratories Ltd.

Business Summary

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Financial Highlights

Mar 2022	INR	USD
Revenue	214,391M	2,877.35M
Gross Profit	113,840M	1,444.68M
Operating income	34,277M	462.79M
Income before tax	31,595M	424.03M
Net income	23,568M	316.30M
EBITDA	46,101M	621.49M
Diluted EPS	141.69	1.90
Dividends Per Share	30	0.40
Total Assets	296,654M	3,864.42M
Total liabilities	106,127M	1,350.04M
Total equity	190,527M	2,514.37M
Operating cash flow	27,636M	370.90M
	Currency in INR	Currency in USD

Historical Data

INR | USD

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	142,028M	153,851M	174,600M	189,722M	214,391M
Gross Profit	71,189M	78,008M	88,078M	96,342M	113,840M
Operating income	11,182M	19,584M	28,637M	32,028M	34,277M
Income before tax	13,997M	22,005M	17,471M	25,933M	31,595M
Net income	9,806M	18,795M	19,498M	17,238M	23,568M
EBITDA	22,892M	31,774M	41,109M	44,824M	46,101M
Diluted EPS	59.01	113.09	117.39	103.64	141.69
Dividends Per Share	20	20	25	25	30
Total Assets	225,604M	225,427M	232,241M	265,491M	296,654M
Total liabilities	99,144M	85,230M	77,253M	92,429M	106,127M
Total equity	126,460M	140,197M	154,988M	173,062M	190,527M
Operating cash flow	17,110M	27,878M	29,249M	35,602M	27,636M

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	2,203.14M	2,199.67M	2,462.41M	2,555.69M	2,877.35M
Gross Profit	1,104.28M	1,115.31M	1,242.17M	1,297.79M	1,444.68M
Operating income	173.45M	280.00M	403.87M	431.44M	462.79M
Income before tax	217.12M	314.61M	246.39M	349.33M	424.03M
Net income	152.11M	268.71M	274.98M	232.20M	316.30M
EBITDA	355.10M	454.28M	579.76M	603.81M	621.49M
Diluted EPS	0.91	1.61	1.65	1.39	1.90
Dividends Per Share	0.31	0.28	0.35	0.33	0.40
Total Assets	3,459.03M	3,254.08M	3,069.88M	3,631.20M	3,864.42M
Total liabilities	1,520.10M	1,230.31M	1,021.17M	1,264.18M	1,350.04M
Total equity	1,938.92M	2,023.77M	2,048.71M	2,367.02M	2,514.37M
Operating cash flow	265.41M	398.58M	412.50M	479.58M	370.90M

Valuation Measures

Mar 2022
PER	30.30
ROA	8.38%
ROE	12.96%
Operating margin	15.98%
Profit margin	10.99%

Key executives

Chief Executive Officer: Erez Israeli
Chief Financial Officer: Parag Agarwal
Chief Digital & Information Officer: Mukesh Rathi
Secretary & Compliance Officer: K. Randhir Singh
CEO-India & Emerging Markets Branded Markets: M. V. Ramana

Shareholders

APS Trust (20.6%)
Life Insurance Corporation of India (Investment Portfolio) (5.6%)
First Sentier Investors (Australia) IM Ltd. (3.5%)
REDDY SATISH KALLAM FAMILY (3.3%)
SBI Funds Management Pvt Ltd. (2.6%)
Aditya Birla Sun Life Amc Ltd. (Investment Management) (2.1%)
BlackRock Fund Advisors (1.9%)
The Vanguard Group, Inc. (1.7%)
ICICI Prudential Asset Management Co. Ltd. (1.7%)
GIC Pte Ltd. (Investment Management) (1.7%)

Contact Details

Website:http://www.drreddys.com
Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
Phone: +91.40.49002900

Related Companies

Dr. Reddys Laboratories Ltd. /4 Brands/
Dr. Reddy's Laboratories Ltd. /2 Brands/
Nimbus Health GmbH
Dr. Reddy's Farmaceutica do Brasil Ltda.
Dr. Reddy's Employees ESOS Trust
Dr. Reddy's Research Foundation
BMS Laboratories Ltd.
Wockhardt Ltd. /Domestic Formulations Bus/
Imperial Credit Pvt Ltd.
Ducere Pharma LLC/Otc Bus/
UCB SA /Established Product Bus/
Dr. Reddy's Laboratories SA
Zenovus Biotech Pvt Ltd.
Regkinetics Services Ltd.
Dr. Reddy's Bio-Sciences Ltd.
Idea2Enterprises (India) Pvt Ltd.
Industrias Quimicas Falcon de Mexico SA de CV
Kunshan Rotam Reddy Pharmaceutical Co., Ltd.
Aurigene Discovery Technologies Ltd.
Perlecan Pharma Pvt Ltd.
Macred India Pvt Ltd.
BASF SE /Pharmaceutical Contract Manufacturing Unit/
Dowpharma /Small Molecules Business/
Laboratorios Litaphar SA
F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
Trigenesis Therapeutics, Inc.

Competitors

Amneal Pharmaceuticals, Inc. Class A
Perrigo Co. Plc
KRKA dd
Teva Pharmaceutical Industries Limited
Hikma Pharmaceuticals Plc
Pfizer Inc.
Novartis AG
Pfizer Limited
Lupin Limited
Sanofi
Bayer AG
Cipla Ltd
Glenmark Pharmaceuticals Limited
Aurobindo Pharma Ltd
Fresenius SE & Co. KGaA
Alkem Laboratories Ltd.
Zydus Lifesciences Limited
Nichi-Iko Pharmaceutical Co., Ltd.
Viatris, Inc.
Sanofi India Limited
Sun Pharmaceutical Industries Limited
Abbott India Limited
GlaxoSmithKline Pharmaceuticals Limited
Endo International Plc
Piramal Enterprises Ltd.
STADA Arzneimittel AG
Syngene International Ltd.
Hindustan Unilever Limited
WuXi AppTec Co., Ltd. Class H
Lonza Group AG

Last Updated on 29 Jun, 2022